Back to GetFilings.com




UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 10-Q

 


 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2004

 

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

For the transition period from              to             

 

Commission file number 1-10145

 


 

LYONDELL CHEMICAL COMPANY

(Exact name of registrant as specified in its charter)

 


 

Delaware   95-4160558

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1221 McKinney Street,

Suite 700, Houston, Texas

  77010
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (713) 652-7200

 


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).    Yes   x    No  ¨

 

Number of shares of common stock outstanding as of June 30, 2004: 178,491,306

(includes common stock, $1.00 par value, and Series B common stock, $1.00 par value)

 


 


PART I. FINANCIAL INFORMATION

 

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

LYONDELL CHEMICAL COMPANY

 

CONSOLIDATED STATEMENTS OF INCOME

 

    For the three
months ended
June 30,


    For the six
months ended
June 30,


 

Millions of dollars, except per share data


  2004

    2003

    2004

    2003

 

Sales and other operating revenues

  $ 1,161     $ 913     $ 2,266     $ 1,902  

Cost of sales

    1,084       866       2,113       1,822  

Selling, general and administrative expenses

    49       45       94       87  

Research and development expenses

    8       8       16       17  
   


 


 


 


      1,141       919       2,223       1,926  
   


 


 


 


Operating income (loss)

    20       (6 )     43       (24 )

Interest expense

    (111 )     (102 )     (222 )     (202 )

Interest income

    3       3       5       20  

Other income (expense), net

    (3 )     (3 )     (4 )     13  
   


 


 


 


Loss before equity investments and income taxes

    (91 )     (108 )     (178 )     (193 )
   


 


 


 


Income (loss) from equity investments:

                               

Equistar Chemicals, LP

    33       (32 )     39       (132 )

LYONDELL-CITGO Refining LP

    63       37       119       56  

Other

    1       (4 )     2       (6 )
   


 


 


 


      97       1       160       (82 )
   


 


 


 


Income (loss) before income taxes

    6       (107 )     (18 )     (275 )

Provision for (benefit from) income taxes

    3       (39 )     (6 )     (94 )
   


 


 


 


Net income (loss)

  $ 3     $ (68 )   $ (12 )   $ (181 )
   


 


 


 


Basic and diluted earnings (loss) per share

  $ 0.02     $ (0.43 )   $ (0.07 )   $ (1.13 )
   


 


 


 


 

See Notes to the Consolidated Financial Statements.

 

1


LYONDELL CHEMICAL COMPANY

 

CONSOLIDATED BALANCE SHEETS

 

Millions, except shares and par value data


   June 30,
2004


    December 31,
2003


 

ASSETS

                

Current assets:

                

Cash and cash equivalents

   $ 455     $ 438  

Accounts receivable:

                

Trade, net

     414       365  

Related parties

     83       84  

Inventories

     327       347  

Prepaid expenses and other current assets

     59       82  

Deferred tax assets

     43       43  
    


 


Total current assets

     1,381       1,359  

Property, plant and equipment, net

     2,533       2,640  

Investments and long-term receivables:

                

Investment in Equistar Chemicals, LP

     1,002       965  

Investment in PO joint ventures

     831       866  

Investment in and receivable from LYONDELL-CITGO Refining LP

     209       232  

Other investments and long-term receivables

     88       85  

Goodwill

     1,080       1,080  

Other assets, net

     382       406  
    


 


Total assets

   $ 7,506     $ 7,633  
    


 


LIABILITIES AND STOCKHOLDERS’ EQUITY

                

Current liabilities:

                

Accounts payable:

                

Trade

   $ 314     $ 284  

Related parties

     156       147  

Accrued liabilities

     244       268  
    


 


Total current liabilities

     714       699  

Long-term debt

     4,152       4,151  

Other liabilities

     686       680  

Deferred income taxes

     768       792  

Commitments and contingencies

                

Minority interest

     138       155  

Stockholders’ equity:

                

Common stock, $1.00 par value, 340,000,000 shares authorized, 142,330,000 shares issued

     142       142  

Series B common stock, $1.00 par value, 80,000,000 shares authorized, 37,879,455 and 36,823,421 shares issued, respectively

     38       37  

Additional paid-in capital

     1,588       1,571  

Retained deficit

     (574 )     (474 )

Accumulated other comprehensive loss

     (98 )     (54 )

Treasury stock, at cost, 1,718,149 and 2,360,834 shares, respectively

     (48 )     (66 )
    


 


Total stockholders’ equity

     1,048       1,156  
    


 


Total liabilities and stockholders’ equity

   $ 7,506     $ 7,633  
    


 


 

See Notes to the Consolidated Financial Statements.

 

2


LYONDELL CHEMICAL COMPANY

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

    

For the six
months

ended June 30,


 

Millions of dollars


   2004

    2003

 

Cash flows from operating activities:

                

Net loss

   $ (12 )     $(181 )

Adjustments to reconcile net loss to net cash provided by operating activities:

                

Depreciation and amortization

     127       118  

(Income) losses from equity investments

     (160 )     82  

Distributions of earnings from affiliates

     120       56  

Deferred income taxes

     (8 )     (92 )

Gain on sale of equity interest

     —         (18 )

Changes in assets and liabilities that provided (used) cash:

                

Accounts receivable

     (56 )     (4 )

Inventories

     17       (14 )

Accounts payable

     50       34  

Income taxes refundable, net of payable

     1       33  

Other assets and liabilities, net

     (1 )     14  
    


 


Net cash provided by operating activities

     78       28  
    


 


Cash flows from investing activities:

                

Expenditures for property, plant and equipment

     (27 )     (238 )

Distributions in excess of earnings from affiliates

     48       102  

Contributions and advances to affiliates

     (22 )     (78 )

Proceeds from sale of equity interest

     —         28  

Maturity of other short-term investments

     —         25  
    


 


Net cash used in investing activities

     (1 )     (161 )
    


 


Cash flows from financing activities:

                

Dividends paid

     (63 )     (57 )

Issuance of long-term debt

     —         318  

Repayment of long-term debt

     —         (103 )

Other

     4       (4 )
    


 


Net cash (used in) provided by financing activities

     (59 )     154  
    


 


Effect of exchange rate changes on cash

     (1 )     1  

Increase in cash and cash equivalents

     17       22  

Cash and cash equivalents at beginning of period

     438       286  
    


 


Cash and cash equivalents at end of period

   $ 455     $ 308  
    


 


 

See Notes to the Consolidated Financial Statements.

 

3


LYONDELL CHEMICAL COMPANY

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

1. Basis of Preparation

 

The accompanying consolidated financial statements are unaudited and have been prepared from the books and records of Lyondell Chemical Company (“Lyondell”) in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X for interim financial information. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting only of normal, recurring adjustments, considered necessary for a fair presentation have been included. For further information, refer to the consolidated financial statements and notes thereto for the year ended December 31, 2003 included in the Lyondell 2003 Annual Report on Form 10-K.

 

2. Employee Stock Options

 

In the first quarter 2003, Lyondell adopted the “fair value” method of accounting for employee stock options, the preferred method as defined by Statement of Financial Accounting Standards (“SFAS”) No. 123, Accounting for Stock-Based Compensation. Lyondell is using the prospective transition method, one of three alternatives under SFAS No. 148, Accounting for Stock-Based Compensation – Transition and Disclosure, for a voluntary change to the fair value method. Under the prospective transition method, an estimate of the fair value of options granted to employees during 2003 and thereafter is charged to earnings over the related vesting periods. This change resulted in an after-tax charge of approximately $1 million for each of the six-month periods ended June 30, 2004 and 2003.

 

Prior to 2003, Lyondell accounted for employee stock options under the intrinsic value method prescribed by Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees. Accordingly, no compensation cost was recognized in connection with stock options granted prior to 2003 under Lyondell’s plans. The pro forma effect on net income and earnings per share of measuring compensation expense for such grants in the manner prescribed in SFAS No. 123 is summarized in the table below:

 

     For the three
months ended
June 30,


    For the six
months ended
June 30,


 

Millions of dollars, except per share data


   2004

   2003

    2004

    2003

 

Reported net income (loss)

   $ 3    $ (68 )   $ (12 )   $ (181 )

Add stock-based compensation

    expense included in net income (loss), net of tax

     —        —         1       1  

Deduct stock-based compensation expense

    using fair value method for all awards, net of tax

     —        (2 )     (1 )     (4 )